VERY LOW NICOTINE CIGARETTES IN SMOKERS WITH SCHIZOPHRENIA

在美国，近一半的烟草消费是由精神病患者吸食的。在 特别是，精神分裂症（SWS）吸烟者很少尝试和实现持续戒烟 并且由于吸烟相关的疾病而缩短了25年的寿命。SWS迫切需要有效的 吸烟治疗，并没有受益于目前可用的治疗。减少尼古丁 将香烟的含量降低到非成瘾水平是一种创新策略， 减少这一人群中与烟草有关的发病率和死亡率。在评估这一潜在影响时， 战略，一个关键的知识差距，确定的是，这种战略是否会有效的吸烟者 患有严重精神疾病，比其他吸烟者更依赖尼古丁， 自我治疗的目的。我们目前正在研究VLNC香烟对SWS的急性影响， 有希望的结果表明使用这些香烟逆转了戒断引起的香烟渴望， 戒断相关的负面情绪和普通品牌的吸烟。此外，SWS对主观效果进行了评分 VLNC香烟高度，表明这种方法可能是可接受的SWS。但效果 长期使用VLNC香烟对吸烟者的精神症状和认知功能的影响 SWS未知。这项研究将是第一个审查是否有一个减少 将香烟中的尼古丁含量降至非成瘾水平是减少吸烟的可行方法。 人口吸烟者将被随机分配到两个实验条件之一：1）非常低的尼古丁含量 （VLNC）尼古丁含量为0.06 mg的香烟（实际剂量由项目1确定; n = 40），或2） 正常尼古丁含量香烟（n = 40）。在2周基线和6周治疗阶段， 将评估受试者的烟草使用模式、暴露的生物标志物、主观反应（例如， 满意度，渴望，戒断症状），精神症状，认知表现，吸烟提示 反应性和吸烟地形。在6周治疗期结束时，主观和行为 将评估对戒烟的反应。这项研究的结果将描述可能的 风险和利益的吸烟者精神分裂症大大减少尼古丁含量的香烟。 该项目将补充和使用与项目1和2类似的措施。 相关性（参见说明）; 吸烟率异常高，与吸烟有关的 吸烟者精神分裂症的发病率和死亡率。该项目将调查6周使用的效果 尼古丁含量极低的香烟对吸烟、情绪、精神症状、认知功能和 精神分裂症吸烟者的其他指标。这些信息将有助于确定是否有公共 将香烟的尼古丁含量限制在很低水平的健康政策对以下人群是有效和安全的： 这些吸烟者

Nearly half of the tobacco consumed in the United States is smoked by people with psychiatric illness. In particular, smokers with schizophrenia (SWS) infrequently attempt and attain sustained smoking abstinence and have a 25-year shorter lifespan due to smoking-related illness. SWS are in dire need of effective smoking treatment and are not benefiting from treatments that are currently available. Reducing the nicotine content of cigarettes to non-addicting levels is an innovative strategy that has the potential to significantly reduce tobacco-related morbidity and mortality in this population. In evaluating the potential impact of this strategy, one critical knowledge gap that was identified is whether this strategy would be effective in smokers with serious mental illness, who are more nicotine-dependent than other smokers and who may smoke for self-medication purposes. We are currently studying the acute effects of VLNC cigarettes in SWS, with promising results showing that use of these cigarettes reverses abstinence-induced cigarette craving, withdrawal-related negative mood and usual-brand smoking. Furthermore, SWS rate the subjective effects VLNC cigarettes highly, indicating that such an approach may be acceptable to SWS. However, the effects of prolonged use of VLNC cigarettes on smoking tiehavior, psychiatric symptoms and cognitive functioning in SWS are unknown. This study would be the first to examine whether a regulatory approach of reducing the nicotine content of cigarettes to non-addicting levels is a viable method of reducing smoking in this population. Smokers will be randomized to one of two experimental conditions: 1) very low nicotine content (VLNC) cigarettes with a 0.06 mg nicotine yield (actual dose to be determined by Project 1; n = 40), or 2) normal nicotine content cigarettes (n = 40). Over the 2-week baseline and 6-week treatment phases, subjects will be assessed for patterns of tobacco use, biomarkers of exposure, subjective responses (e.g., satisfaction, craving, withdrawal symptoms), psychiatric symptoms, cognitive performance, smoking cue reactivity and smoking topography. At the end of the 6-week treatment period, subjective and behavioral responses to smoking abstinence will be assessed. The results from this study will describe the possible risks and benefits to smokers with schizophrenia of dramatically reducing the nicotine content of cigarettes. This project will complement and use similar measures as Projects 1 and 2. RELEVANCE (See instructions); There is an unusually high rate of cigarette smoking and correspondingly high rates of smoking-related morbidity and mortality in smokers with schizophrenia. This project will investigate the effects of 6-week use of very low nicotine content cigarettes on smoking, mood, psychiatric symptoms, cognitive functioning and other measures in smokers with schizophrenia. This information will help to determine whether a public health policy of limiting the nicotine content of cigarettes to very low levels would be effective and safe for these smokers